Furthermore, various evidence have suggested that some melanomas have intrinsic activation of the PI3K pathway44 whereas the activated PI3K pathway has also been implicated in the development of resistance of melanoma tumours to BRAF/MEK inhibitors45–48 and to immune checkpoint inhibitors49,50. This evidence concerns the gene BRAF and melanoma.